Member Profile

Established in June 2010, TWi Biotechnology focuses on the development of new drugs for innate immunity-related diseases, especially in the areas of rare and dermatological disorders. Leveraging its extensive experience in clinical, pre-clinical and pharmacology/toxicology studies, local and international regulations, and deep knowledge of global patent protection and business licensing, as well as track record of specialty drugs development in the US, TWi Biotechnology assumes a leading position in clinical research and drug development.
The mission of TWi Biotechnology is to fulfil the unmet medical needs, where effective or novel treatment is still not available, for example serious rare diseases. In addition, there is high demand for development of new treatments due to changes in disease management and breakthrough research in disease pathogenesis. In order to achieve innovation and to create value for the company rapidly, TWi Biotechnology has adopted a drug repositioning strategy with the aim to efficiently develop safe and effective new drugs to fulfill the unmet medical need, especially focusing on the severe and no approved treatment of rare diseases such as epidermolysis bullosa simplex.